Chronic Obstructive Pulmonary Disease Treatment Market 2027 by Drug Class, Distribution Channel | The Insight Partners

Chronic Obstructive Pulmonary Disease Treatment Market Forecast to 2027 - Covid-19 Impact and Global Analysis - by Drug Class (Bronchodilators, Combination, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids, Others); Distribution Channel (Online Pharmacies, Hospital Pharmacies, Retail Pharmacies)

Report Code: TIPRE00008520 | No. of Pages: 150 | Category: Medical Device | Status: Upcoming
Covid
MARKET INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is a common lung disease. Having COPD makes it hard to breathe. Two primary forms of COPD are chronic bronchitis, which involves a long-term cough with mucus. Emphysema involves damage to the lungs over time.

MARKET DYNAMICS

The chronic obstructive pulmonary disease treatment market is anticipated to grow due to increasing the need for COPD management. However, patent expiry of branded products and the availability of generic equivalents and alternative treatment options, which is restraining the market growth. Moreover, the high prevalence of the chronic obstructive pulmonary disease, rise in geriatric population, surge in the patient population, and growth of the healthcare industry is expected to benefit the growth of the market in the forecast period.

MARKET SCOPE

The "Chronic Obstructive Pulmonary Disease Treatment Market Analysis to 2027" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of in chronic obstructive pulmonary disease treatment market with detailed market segmentation by type, reptile, mode of action and geography. The chronic obstructive pulmonary disease treatment market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading in chronic obstructive pulmonary disease treatment market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The chronic obstructive pulmonary disease treatment market is segmented on the basis of drug class and distribution channel. Based on drug class the market is segmented as bronchodilators, combination, phosphodiesterase type 4 inhibitors, mucokinetics, corticosteroids and others. On the basis of reptile the market is categorized as online pharmacies, hospital pharmacies and retail pharmacies.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the in chronic obstructive pulmonary disease treatment market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The chronic obstructive pulmonary disease treatment market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting chronic obstructive pulmonary disease treatment market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the chronic obstructive pulmonary disease treatment market in these regions.




Get more information on this report :

MARKET PLAYERS


The report covers key developments in the in chronic obstructive pulmonary disease treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from in chronic obstructive pulmonary disease treatment market are anticipated to have lucrative growth opportunities in the future with the rising demand for in chronic obstructive pulmonary disease treatment market in the global market. Below mentioned is the list of few companies engaged in the chronic obstructive pulmonary disease treatment market.

The report also includes the profiles of key in chronic obstructive pulmonary disease treatment market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

- Abbott
- AstraZeneca
- BoehringerIngelheim Pharmaceuticals, Inc.
- CHIESI Farmaceutici S.p.A.
- GlaxoSmithKline plc
- Mylan N.V.
- Novartis AG
- Orion Corporation
- Sunovion Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Chronic Obstructive Pulmonary Disease Treatment Market - By Drug Class
1.3.2 Chronic Obstructive Pulmonary Disease Treatment Market - By Distribution Channel
1.3.3 Chronic Obstructive Pulmonary Disease Treatment Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET - GLOBAL MARKET ANALYSIS
6.1. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT - GLOBAL MARKET OVERVIEW
6.2. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. BRONCHODILATORS
7.3.1. Overview
7.3.2. Bronchodilators Market Forecast and Analysis
7.4. COMBINATION
7.4.1. Overview
7.4.2. Combination Market Forecast and Analysis
7.5. PHOSPHODIESTERASE TYPE 4 INHIBITORS
7.5.1. Overview
7.5.2. Phosphodiesterase Type 4 Inhibitors Market Forecast and Analysis
7.6. MUCOKINETICS
7.6.1. Overview
7.6.2. Mucokinetics Market Forecast and Analysis
7.7. CORTICOSTEROIDS
7.7.1. Overview
7.7.2. Corticosteroids Market Forecast and Analysis
7.8. OTHERS
7.8.1. Overview
7.8.2. Others Market Forecast and Analysis
8. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
8.3. ONLINE PHARMACIES
8.3.1. Overview
8.3.2. Online Pharmacies Market Forecast and Analysis
8.4. HOSPITAL PHARMACIES
8.4.1. Overview
8.4.2. Hospital Pharmacies Market Forecast and Analysis
8.5. RETAIL PHARMACIES
8.5.1. Overview
8.5.2. Retail Pharmacies Market Forecast and Analysis
9. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Chronic Obstructive Pulmonary Disease Treatment Market Overview
9.1.2 North America Chronic Obstructive Pulmonary Disease Treatment Market Forecasts and Analysis
9.1.3 North America Chronic Obstructive Pulmonary Disease Treatment Market Forecasts and Analysis - By Drug Class
9.1.4 North America Chronic Obstructive Pulmonary Disease Treatment Market Forecasts and Analysis - By Distribution Channel
9.1.5 North America Chronic Obstructive Pulmonary Disease Treatment Market Forecasts and Analysis - By Countries
9.1.5.1 United States Chronic Obstructive Pulmonary Disease Treatment Market
9.1.5.1.1 United States Chronic Obstructive Pulmonary Disease Treatment Market by Drug Class
9.1.5.1.2 United States Chronic Obstructive Pulmonary Disease Treatment Market by Distribution Channel
9.1.5.2 Canada Chronic Obstructive Pulmonary Disease Treatment Market
9.1.5.2.1 Canada Chronic Obstructive Pulmonary Disease Treatment Market by Drug Class
9.1.5.2.2 Canada Chronic Obstructive Pulmonary Disease Treatment Market by Distribution Channel
9.1.5.3 Mexico Chronic Obstructive Pulmonary Disease Treatment Market
9.1.5.3.1 Mexico Chronic Obstructive Pulmonary Disease Treatment Market by Drug Class
9.1.5.3.2 Mexico Chronic Obstructive Pulmonary Disease Treatment Market by Distribution Channel
9.2. EUROPE
9.2.1 Europe Chronic Obstructive Pulmonary Disease Treatment Market Overview
9.2.2 Europe Chronic Obstructive Pulmonary Disease Treatment Market Forecasts and Analysis
9.2.3 Europe Chronic Obstructive Pulmonary Disease Treatment Market Forecasts and Analysis - By Drug Class
9.2.4 Europe Chronic Obstructive Pulmonary Disease Treatment Market Forecasts and Analysis - By Distribution Channel
9.2.5 Europe Chronic Obstructive Pulmonary Disease Treatment Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Chronic Obstructive Pulmonary Disease Treatment Market
9.2.5.1.1 Germany Chronic Obstructive Pulmonary Disease Treatment Market by Drug Class
9.2.5.1.2 Germany Chronic Obstructive Pulmonary Disease Treatment Market by Distribution Channel
9.2.5.2 France Chronic Obstructive Pulmonary Disease Treatment Market
9.2.5.2.1 France Chronic Obstructive Pulmonary Disease Treatment Market by Drug Class
9.2.5.2.2 France Chronic Obstructive Pulmonary Disease Treatment Market by Distribution Channel
9.2.5.3 Italy Chronic Obstructive Pulmonary Disease Treatment Market
9.2.5.3.1 Italy Chronic Obstructive Pulmonary Disease Treatment Market by Drug Class
9.2.5.3.2 Italy Chronic Obstructive Pulmonary Disease Treatment Market by Distribution Channel
9.2.5.4 Spain Chronic Obstructive Pulmonary Disease Treatment Market
9.2.5.4.1 Spain Chronic Obstructive Pulmonary Disease Treatment Market by Drug Class
9.2.5.4.2 Spain Chronic Obstructive Pulmonary Disease Treatment Market by Distribution Channel
9.2.5.5 United Kingdom Chronic Obstructive Pulmonary Disease Treatment Market
9.2.5.5.1 United Kingdom Chronic Obstructive Pulmonary Disease Treatment Market by Drug Class
9.2.5.5.2 United Kingdom Chronic Obstructive Pulmonary Disease Treatment Market by Distribution Channel
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Market Overview
9.3.2 Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Market Forecasts and Analysis
9.3.3 Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Market Forecasts and Analysis - By Drug Class
9.3.4 Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Market Forecasts and Analysis - By Distribution Channel
9.3.5 Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Chronic Obstructive Pulmonary Disease Treatment Market
9.3.5.1.1 Australia Chronic Obstructive Pulmonary Disease Treatment Market by Drug Class
9.3.5.1.2 Australia Chronic Obstructive Pulmonary Disease Treatment Market by Distribution Channel
9.3.5.2 China Chronic Obstructive Pulmonary Disease Treatment Market
9.3.5.2.1 China Chronic Obstructive Pulmonary Disease Treatment Market by Drug Class
9.3.5.2.2 China Chronic Obstructive Pulmonary Disease Treatment Market by Distribution Channel
9.3.5.3 India Chronic Obstructive Pulmonary Disease Treatment Market
9.3.5.3.1 India Chronic Obstructive Pulmonary Disease Treatment Market by Drug Class
9.3.5.3.2 India Chronic Obstructive Pulmonary Disease Treatment Market by Distribution Channel
9.3.5.4 Japan Chronic Obstructive Pulmonary Disease Treatment Market
9.3.5.4.1 Japan Chronic Obstructive Pulmonary Disease Treatment Market by Drug Class
9.3.5.4.2 Japan Chronic Obstructive Pulmonary Disease Treatment Market by Distribution Channel
9.3.5.5 South Korea Chronic Obstructive Pulmonary Disease Treatment Market
9.3.5.5.1 South Korea Chronic Obstructive Pulmonary Disease Treatment Market by Drug Class
9.3.5.5.2 South Korea Chronic Obstructive Pulmonary Disease Treatment Market by Distribution Channel
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Chronic Obstructive Pulmonary Disease Treatment Market Overview
9.4.2 Middle East and Africa Chronic Obstructive Pulmonary Disease Treatment Market Forecasts and Analysis
9.4.3 Middle East and Africa Chronic Obstructive Pulmonary Disease Treatment Market Forecasts and Analysis - By Drug Class
9.4.4 Middle East and Africa Chronic Obstructive Pulmonary Disease Treatment Market Forecasts and Analysis - By Distribution Channel
9.4.5 Middle East and Africa Chronic Obstructive Pulmonary Disease Treatment Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Chronic Obstructive Pulmonary Disease Treatment Market
9.4.5.1.1 South Africa Chronic Obstructive Pulmonary Disease Treatment Market by Drug Class
9.4.5.1.2 South Africa Chronic Obstructive Pulmonary Disease Treatment Market by Distribution Channel
9.4.5.2 Saudi Arabia Chronic Obstructive Pulmonary Disease Treatment Market
9.4.5.2.1 Saudi Arabia Chronic Obstructive Pulmonary Disease Treatment Market by Drug Class
9.4.5.2.2 Saudi Arabia Chronic Obstructive Pulmonary Disease Treatment Market by Distribution Channel
9.4.5.3 U.A.E Chronic Obstructive Pulmonary Disease Treatment Market
9.4.5.3.1 U.A.E Chronic Obstructive Pulmonary Disease Treatment Market by Drug Class
9.4.5.3.2 U.A.E Chronic Obstructive Pulmonary Disease Treatment Market by Distribution Channel
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Chronic Obstructive Pulmonary Disease Treatment Market Overview
9.5.2 South and Central America Chronic Obstructive Pulmonary Disease Treatment Market Forecasts and Analysis
9.5.3 South and Central America Chronic Obstructive Pulmonary Disease Treatment Market Forecasts and Analysis - By Drug Class
9.5.4 South and Central America Chronic Obstructive Pulmonary Disease Treatment Market Forecasts and Analysis - By Distribution Channel
9.5.5 South and Central America Chronic Obstructive Pulmonary Disease Treatment Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Chronic Obstructive Pulmonary Disease Treatment Market
9.5.5.1.1 Brazil Chronic Obstructive Pulmonary Disease Treatment Market by Drug Class
9.5.5.1.2 Brazil Chronic Obstructive Pulmonary Disease Treatment Market by Distribution Channel
9.5.5.2 Argentina Chronic Obstructive Pulmonary Disease Treatment Market
9.5.5.2.1 Argentina Chronic Obstructive Pulmonary Disease Treatment Market by Drug Class
9.5.5.2.2 Argentina Chronic Obstructive Pulmonary Disease Treatment Market by Distribution Channel
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET, KEY COMPANY PROFILES
11.1. ABBOTT
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. ASTRAZENECA
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. BOEHRINGERINGELHEIM PHARMACEUTICALS, INC.
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. CHIESI FARMACEUTICI S.P.A.
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. GLAXOSMITHKLINE PLC
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. MYLAN N.V.
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. NOVARTIS AG
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. ORION CORPORATION
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. SUNOVION PHARMACEUTICALS, INC.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. TEVA PHARMACEUTICAL INDUSTRIES LTD.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies

1. Abbott
2. AstraZeneca
3. BoehringerIngelheim Pharmaceuticals, Inc.
4. CHIESI Farmaceutici S.p.A.
5. GlaxoSmithKline plc
6. Mylan N.V.
7. Novartis AG
8. Orion Corporation
9. Sunovion Pharmaceuticals, Inc.
10. Teva Pharmaceutical Industries Ltd.
TIPRE00008520
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking